Corticobasal degeneration
ICD-10 G31.85 is a billable code used to indicate a diagnosis of corticobasal degeneration.
Corticobasal degeneration (CBD) is a rare neurodegenerative disorder characterized by progressive asymmetric motor symptoms, cognitive decline, and behavioral changes. It typically manifests in middle to late adulthood and is associated with the accumulation of abnormal tau protein in the brain. Patients often present with symptoms such as rigidity, bradykinesia, and dystonia, primarily affecting one side of the body. Cognitive impairment may include difficulties with executive function, visuospatial skills, and language, resembling aspects of Alzheimer's disease but with distinct clinical features. As the disease progresses, patients may experience apraxia, which is the inability to perform purposeful movements, and alien limb phenomenon, where one limb acts independently of the individual's control. Diagnosis is primarily clinical, supported by neuroimaging findings that may show atrophy in specific brain regions. Given its overlap with other neurodegenerative diseases, accurate diagnosis and coding are crucial for appropriate management and research purposes.
Detailed neurological examination findings, neuroimaging results, and cognitive assessments.
Patients presenting with asymmetric motor symptoms and cognitive decline.
Ensure documentation captures the unique features of CBD to differentiate from other dementias.
Comprehensive geriatric assessment including cognitive and functional status evaluations.
Older adults with progressive cognitive decline and motor symptoms.
Consideration of comorbidities and their impact on overall health and management.
Used for follow-up visits in patients with CBD for management of symptoms.
Document the patient's history, examination findings, and any changes in treatment.
Neurologists should ensure detailed notes on cognitive assessments and motor function.
Primary symptoms include asymmetric rigidity, bradykinesia, cognitive decline, apraxia, and alien limb phenomenon. Patients may also experience behavioral changes and difficulties with speech.
